JAN Stock Analysis: Janus Living | NYSE
REIT - Residential | NYSE, USA | Market Cap: 9.426m USD | 12M Return: 27.9% | US4710241096 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 47.1M
Warnings
Tailwinds
Seasonality 0.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Janus Living, Inc. (NYSE: JAN) is a Denver-based real estate investment trust (REIT) focused exclusively on the U.S. senior housing sector. The company is headquartered in Denver, Colorado, and positions itself as the only U.S. publicly traded REIT dedicated solely to senior housing properties. Its portfolio is operated entirely under RIDEA (REIT Investment Diversification and Empowerment Act) structures, which allow REITs to participate in both rental income and operating income through taxable REIT subsidiary (TRS) arrangements, rather than relying on traditional triple-net lease models.
As of December 31, 2025, Janus Livings initial portfolio consisted of 34 senior housing communities totaling 10,422 units, located primarily in major retirement markets across 10 U.S. states. Geographic concentration is significant, with units in Florida and Texas representing 69% of total units-a reflection of those states longstanding appeal as retirement destinations due to warm climates and favorable tax environments.
Under its RIDEA structure, the operators of Janus Livings communities generate revenue primarily through direct resident payments rather than governmental reimbursement programs such as Medicare or Medicaid. This arrangement, common in private-pay senior housing segments like independent living, assisted living, and memory care, provides the REIT with greater cash flow visibility compared to operators reliant on government payors. Janus Living is classified under the GICS Real Estate sector and the Multi-Family Residential REITs sub-industry.
- Senior housing demand rises with aging baby boomer population
- Geographic concentration in Florida and Texas limits regional diversification
- RIDEA structure avoids Medicare/Medicaid reimbursement risk
| Net Income: 37.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -2.36 > 1.0 |
| NWC/Revenue: 123.5% < 20% (prev -131.6%; Δ 255.1% < -1%) |
| CFO/TA 0.01 > 3% & CFO 70.3m > Net Income 37.4m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 2.26 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (180.9m) vs prev 0.0% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 20.26% > 50% (prev 24.26%; Δ -4.00% > 0%) |
| Interest Coverage Ratio: -0.12 > 6 (EBIT TTM -321k / Interest Expense TTM 2.60m) |
| A: 0.19 (Total Current Assets 1.58b - Total Current Liabilities 699.2m) / Total Assets 4.71b |
| B: -0.01 (Retained Earnings -31.8m / Total Assets 4.71b) |
| C: -0.00 (EBIT TTM -321k / Avg Total Assets 3.53b) |
| D: 2.72 (Book Value of Equity 2.74b / Total Liabilities 1.01b) |
| Altman-Z'' = 4.07 = AA |
| DSRI: 0.19 (Receivables 24.1m/100.8m, Revenue 714.6m/568.5m) |
| GMI: 1.0 (GM 100.0% / 100.0%) |
| AQI: 0.85 (AQ_t 0.20 / AQ_t-1 0.24) |
| SGI: 1.26 (Revenue 714.6m / 568.5m) |
| TATA: -0.01 (NI 37.4m - CFO 70.3m) / TA 4.71b) |
| Beneish M = -3.60 (Cap -4..+1) = AAA |
As of September 27, 2026, the stock is trading at USD 30.05 with a total of 1,125,949 shares traded. Over the past week, the price has changed by -0.96%, over one month by -4.00%, over three months by +4.40% and over the past year by +27.93%.
Current recommended Stop Loss: 28.30 (which is 5.8% or 2.1 ATR below the current price).
Janus Living has no consensus analysts rating.
P/S = 13.0374
P/B = 2.5965
Revenue TTM = 714.6m USD
EBIT TTM = -321k USD
EBITDA TTM = 171.5m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 7.87b USD (9.43b + (null Debt) - CCE 1.56b)
Interest Coverage Ratio = -0.12 (Ebit TTM -321k / Interest Expense TTM 2.60m)
EV/FCF = 478.4x (Enterprise Value 7.87b / FCF TTM 16.4m)
FCF Yield = 0.21% (FCF TTM 16.4m / Enterprise Value 7.87b)
FCF Margin = 2.30% (FCF TTM 16.4m / Revenue TTM 714.6m)
Net Margin = 5.23% (Net Income TTM 37.4m / Revenue TTM 714.6m)
Gross Margin = unknown ((Revenue TTM 714.6m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.67 (Enterprise Value 7.87b / Total Assets 4.71b)
Interest Expense / Debt = unknown (Interest Expense 2.60m / Debt none)
Taxrate = 10.25% (4.06m / 39.7m)
NOPAT = -288k (EBIT -321k * (1 - 10.25%)) [loss with tax shield]
Current Ratio = 2.26 (Total Current Assets 1.58b / Total Current Liabilities 699.2m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 171.5m)
Debt / FCF = unknown (Net Debt none / FCF TTM 16.4m)
Total Stockholder Equity = 1.77b (last fiscal year from totalStockholderEquity)
RoA = 1.06% (Net Income 37.4m / Total Assets 4.71b)
RoE = 2.11% (Net Income TTM 37.4m / Total Stockholder Equity 1.77b)
RoCE = -0.01% (EBIT -321k / Capital Employed (Total Assets 4.71b - Current Liab 699.2m))
RoIC = -0.01% (negative operating profit) (NOPAT -288k / Invested Capital 3.98b)
WACC = 4.60% (E(9.43b)/V(9.43b) * Re(4.60%) + (debt-free company))
Discount Rate = 4.60% (= CAPM, Blume Beta Adj.)
[DCF] Terminal Value 73.10% ; FCFF base≈35.3m ; Y1≈30.9m ; Y5≈25.0m
[DCF] Fair Price = 1.71 (EV 401.1m - Net Debt 0.0 = Equity 401.1m / Shares 234.4m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.02 | Chg30d=-62.38% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=0.18 | Chg30d=-24.80% | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+55.3%
EPS next Year (2027-12-31): EPS=0.19 | Chg30d=-32.99% | Revisions=+17% | GrowthEPS=+3.3% | GrowthRev=+29.5%
[Analyst] Revisions Ratio: +0% (up=3, down=3)